Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages
MR Walker, A Underwood, KH Björnsson… - Communications …, 2024 - nature.com
The continuous emergence of SARS-CoV-2 variants of concern has rendered many
therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically …
therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically …
Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance
A Djaïleb, É Lavallée, MF Parker, MP Cayer… - Frontiers in …, 2023 - frontiersin.org
Introduction Early in the COVID-19 pandemic, reagent availability was not uniform, and
infrastructure had to be urgently adapted to undertake COVID-19 surveillance. Methods …
infrastructure had to be urgently adapted to undertake COVID-19 surveillance. Methods …
A multivariant surrogate neutralization assay identifies variant-specific neutralizing antibody profiles in primary SARS-CoV-2 Omicron infection
DN Springer, M Traugott, E Reuberger, KB Kothbauer… - Diagnostics, 2023 - mdpi.com
Primary infection with the Omicron variant of Severe Acute Respiratory Syndrome Corona
Virus 2 (SARS-CoV-2) can be serologically identified with distinct profiles of neutralizing …
Virus 2 (SARS-CoV-2) can be serologically identified with distinct profiles of neutralizing …
Characterization of SARS‐CoV‐2 humoral immune response in a subject with unique sampling: A case report
Background The development of vaccine candidates for COVID‐19, and the administration
of booster vaccines, has meant a significant reduction in COVID‐19 related deaths world …
of booster vaccines, has meant a significant reduction in COVID‐19 related deaths world …
Novel, broad and potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages
The continuous emergence of SARS-CoV-2 variants of concern with mutated spike receptor
binding domains has rendered many therapeutic mAbs ineffective. To date, there are no …
binding domains has rendered many therapeutic mAbs ineffective. To date, there are no …